Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3056-3059

  Jain, Nareshkumar ^a   Kanojia, Ramesh M ^a   Xu, Jiayi ^a   Jian Zhong, Guo ^a   Pacia, Emmanuel ^a   Lai, Muh Tsann ^a   Du, Fuyong ^a   Musto, Amy ^a   Allan, George ^a   Hahn, DoWon ^a   Lundeen, Scott ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPYRAN DERIVATIVE; CHOLESTEROL; CHROMENE DERIVATIVE; ETHINYLESTRADIOL; LY 357489; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANTIESTROGEN ACTIVITY; ARTICLE; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG USE; ENANTIOMER; ESTROGEN ACTIVITY; EVALUATION RESEARCH; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; VAGINAL DRYNESS;

ANIMALS; BENZOPYRANS; BODY FLUIDS; BONE DENSITY; CELL LINE; CHOLESTEROL; FEMALE; HOT FLASHES; HUMANS; ORGAN SIZE; OVARIECTOMY; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEREOISOMERISM; UTERUS; VAGINA; VAGINAL DISEASES;

EID: 33744791784     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060353u     Document Type: Article

References (43)

1. For recent reviews, see the following: (a) Jordan, V. C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines., Receptor Interactions. J. Med. Chem. 2003, 46, 883-908.
2. (b) Jordan, V. C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines, Clinical Considerations and New Agents. J. Med. Chem. 2003, 46, 1081-1111.
3. (c) Riggs, B. L.; Hartmann, L. C. Selective Estrogen-Receptor Modulators-Mechanisms of Action and Application to Clinical Practice. N. Engl. J. Med. 2003, 348, 618-629.
4. (d) Freedman, R. R. Physiology of Hot Flashes. Am. J. Hum. Biol. 2001, 13, 454-464.
5. (a) Shanafelt, T. D.; Barton, D. L.; Adjei, A. A.; Loprinzi, C. L. Pathphysiology and Treatment of Hot Flashes. Mayo Clin. Proc. 2002, 77, 1207-1218.
6. For recent reports, see the following: Simunic, V.; Banovic, I.; Ciglar, S.; Jeren, L.; Pavicic Baldani, D.; Sprem, M. Local estrogen treatment in patients with urogenital symptoms. Intl. J. Gynecol. Obstet. 2003, 82 (2), 187-197
7. (b) Miller, C. P. SERMs: Evolutionary Chemistry, Revolutionary Biology. Curr. Pharm. Des. 2002, 8 (23), 2089-2111
8. (c) Kenemans, P.; Speroff, L. SERMs: Evolutionary Chemistry, Revolutionary Biology. Maturitas 2005, 51 (1), 21-28
9. (d) Oskay, U. Y.; Beji, N. K.; Yalcin, O. Acta obstetrician A study on urogenital complaints of postmenopausal women aged 50 and over. Gynecol. Scand. 2005, 84 (1), 72-78.
10. (e) Bachmann G. Urogenital aging: an old problem newly recognized. Maturitas 1995, 22 Suppl S1-S5.
11. (a) Seibel, M. M. Freedman, R. R. Physiology of Hot Flashes. Am. J. Hum. Biol. 2001, 13, 454-464.
12. (b) Plouffe, L., Jr.; Facoq, C. M. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice. J. Soc. Gynecol. Invest. 2000, 7, S38-S46.
13. (a) Hulley, S.; Grady, D.; Bush, T.; et al. Randomized Trial of Estrogen plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. J. Am. Med. Assoc. 1998, 280, 605-613.
14. (b) Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and Hormone Replacement Therapy. Lancet 1997, 350, 1047-1059
15. (c) Gauthier, Sylvain; Cloutier, Julie; Dory, Yves L.; Favre. Alexandre; Mailhot, Josee; Quellet, Carl; Schwerdtfeger. Annette: Merand, Yves; Martel, Celine; Simard, Jacques; Labrie, Fernand. Synthesis and structure-activity relationships of analogues of EM-652 (acolbifene), a pure selective estrogen receptor modulator. J. Enzyme Inhib. Med. Chem. 2005, 20 (2), 165-177.
16. (d) Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J. Med. Chem. 1998, 41, 1272.
17. (a) Davies, G. C.; Huster, M. W. J.; Lu, Y.; Plouffe, L., Jr.; Lakshmanan, M. Adverse Events Reported by Postmenopausal Women in Controlled Trials with Raloxifene. Obstet. Gynecol. 1999, 93, 558-565.
18. (b) Loprinzi, C. L.; Zahasky, K. M.; Slaoan, J. A.; Novotny, P. J.; Quella, S. K. Tamoxifen-Induced Hot Flashes. Clin. Breast Cancer 2000, 1, 52-56.
19. Kanojia, R. M.; Jain, N. F.; Ng, R.; Sui, Z.; Xu, J. Preparation of tetracyclic heterocycles as selective estrogen receptor modulators (SERMs) WO 2003053977, 2003. US 71997520031121, 2004.
20. For synthesis of the tetracyclic core structure, see (a) Kanojia, R. M.; Jain, N.; Xu, J.; Sui, Z. Preparation of tetracyclic heterocycles as selective estrogen receptor modulators (SERMs). Tetrahedron Lett. 2004, 45, 5837-5839.
21. (b) Jain, N.; Xu, J.; Chen, N.; Sui, Z. A novel approach to the synthesis of 11,11-diinethyl-bisbenzopyran-5-ones. Tetrahedron Lett. 2006, 47, 225-228.
22. (a) The absolute configuration of 1-(R) and 1-(S) has been determined by VCD spectroscopy data.
23. (b) ee values were > 95; optical purities were determined by chiral Pak AD column.
24. Allan, G. F.; Hutchins, A.; Clancy, J. An ultrahigh-throughput screening assay for estrogen receptor ligands. Anal. Biochem. 1999, 275, 243-247.
25. (b) Rufbin, V. N.; Ruenitz, P. C.; Boyd, J. L.; Boudinot, F. D.; Wiese, T. E. Characterization of Selective Estrogen Receptor Modulator (SERM) Activity in Two Triarylethylene Oxybutyric Acids. Biochem. Pharmacol. 2002, 63, 1517-1525.
26. Wang, T. T.; Sathyamoorthy, N.; Phang, J. M. Molecular Effects of Genistein on Estrogen Receptor Mediated Pathways. Carcinogenesis 1996, 17, 271-275.
27. Possible path way for auto oxidation is described in ref 8b.
28. (a) Komm B. S.; Rusling D. J.; Lyttle C. R. Estrogen regulation of protein synthesis in the immature rat uterus: the analysis of proteins released into the medium during in vitro incubation. Endocrinology 1986, 118, 2411-2416.
29. (b) Komm, B. S.; Kharode, Y. P.; Bodine, P. V. N.; Harris, H. A.; Miller, C. P.; Lyttle, C. R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146 (9), 3999-4008.
30. (a) Komm, B. S.; Lyttle, C. R. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann. N.Y. Acad. Sci. 2001, 949, 317-326.
31. (b) Ashby J.; Odum, J.; Foster, J. R. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Toxicol Pharmacol 1997, 25, 226-231.
32. (c) Qu, Q.; Zheng, H.; Dahllund, J.; Laine, A.; Cockcroft, N.; Peng, Z.; Koskinen, M.; Hemminki, K.; Kangas, L.; Väänänen, K.; Härkönen, P. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000, 141, 809-820.
33. (d) Sato, M.; Turner, C. H.; Wang, T.; Adrian, M. D.; Rowley, E.; Bryant, H. U. J. LY353381.HCl: a novel raloxifene analogue with improved SERM potency and efficacy in vivo. Pharmacol. Exp. Ther. 1998, 287, 1-7.
34. Geiser, A. G.; Hummel, C. W.; Draper, M. W.; Henck, J. W.; Cohen, I. R.; Rudmann, D. G.; Donnelly, K. B.; Adrian, M. D.; Shepherd, T. A.; Wallace, O. B.; McCann, D. J.; Oldham, S. W.; Bryant, H. U.; Sato, M.; Dodge, J. A. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 2005, 146 (10), 4524-4535.
35. (a) Simpkins, J. W.; Katovich, M. J.; Song, I.-C. Chronic hyperprolactinemia reduces peripheral beta-adrenergic responsiveness in male rats. Life Sci. 1983, 32, 1957-1966.
36. (b) Katovich, M. J.; Simpkins, J. W.; Berglund, L. A.; O'Meara, J. Regional skin temperature changes in a rat model for the menopausal hot flush. Maturitas 1986, 8, 67-76.
37. (c) Merchenthaler, I.; Funkhouser, J. M.; Carver, J. M.; Lundeen, S. G.; Ghosh, K.; Winneker, R. C. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998, 30, 307-316.
38. Both 1-(R) and 1-(S) have similar pharmacokinetic properties in rats. The active metabolites 2d-(R) and 2d-(S) were detected in plasma predominantly with similar exposures as compared to the parent compounds 1-(R) and 1-(S), respectively. The total bioavailability calculated for 1-(R) and 1-(S) was about 11% and 9%, respectively. The partial hydrolyzed products were not detected in rat plasma.
39. (a) The concentration of these compounds in blood was not determined in the immature uterotropic assays.
40. (b) From our PK study, we have shown that 1-(R) and 1-(S) are extensively metabolized to 2d-(R) and 2d-(S), respectively. To correct the molecular weight change, a 1.4 mg/kg dose was chosen as standard screening dose.
41. (a) Matsumoto, T.; Morii, H.; Yazaki, Y.; Ouchi, Y., Eds. Selective Estrogen Receptor Modulators. Clin. Calcium 2002, 12 (12), 102 pp.
42. (b) For a detailed description of the current understanding of tissue-specific steroid hormone activities, see Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
43. See Supporting Information for details.